|1.||Franchini, Massimo: 10 articles (06/2014 - 11/2006)|
|2.||Santoso, Sentot: 10 articles (09/2013 - 03/2005)|
|3.||Borza, Dorin-Bogdan: 8 articles (05/2013 - 05/2003)|
|4.||Kroll, Hartmut: 7 articles (09/2013 - 03/2005)|
|5.||Sachs, Ulrich J: 6 articles (10/2013 - 11/2011)|
|6.||Porcelijn, Leendert: 5 articles (11/2015 - 01/2009)|
|7.||Greinacher, Andreas: 5 articles (09/2015 - 05/2006)|
|8.||Bakchoul, Tamam: 5 articles (03/2014 - 10/2009)|
|9.||Lippi, Giuseppe: 5 articles (10/2013 - 11/2006)|
|10.||Bein, Gregor: 5 articles (09/2013 - 05/2009)|
|1.||Hemophilia A (Haemophilia)
10/01/2011 - "The management of patients with congenital haemophilia who develop alloantibodies against factors of the propagation phase of blood coagulation, commonly known as inhibitors, is the most important challenge facing haemophilia caregivers at present, as this complication not only compromises the efficacy of replacement therapy but also consumes an enormous amount of economic resources. "
06/01/2014 - "In addition, a number of investigators have recently used this agent in patients with congenital haemophilia A or B and alloantibodies refractory to first-line treatment. "
04/22/1999 - "Haemophilia A patients who receive repeated transfusion of fVIII concentrates often develop inhibitor alloantibodies, resulting in reduced efficacy of the therapy. "
08/01/2014 - "The development of factor (F) VIII neutralizing alloantibodies (inhibitors) is a major complication of treatment with FVIII concentrates in hemophilia A and the etiology is still poorly understood. "
10/01/2013 - "It is concluded that C domain of FVIII is one of the primary binding sites for the alloantibodies against FVIII in Chinese patients with hemophilia A."
02/01/2008 - "Both products are highly effective in controlling bleeding in the presence of inhibitory alloantibodies, yet their hemostatic efficacy can be unpredictable. "
10/01/2013 - "Although the ultimate goal of treatment of patients with alloantibodies against factors VIII and IX is eradication of the inhibitor, the control of bleeding through high doses of factor concentrates (low titer inhibitors) or bypassing agents (high titer inhibitors) is the mainstay of management of these patients. "
10/01/2011 - "While the short-term goal of treatment of patients who develop alloantibodies is the control of bleeding, the eradication of the inhibitor is the main long-term goal. "
06/01/2009 - "In this review, we summarize the current literature data on the occurrence of anaphylactoid reactions in patients with inherited bleeding disorders and alloantibodies. "
11/19/2005 - "[Severe bleeding in a patient with anti-c alloantibodies and a rare Rhesus phenotype treated with compatible erythrocyte concentrate from the blood bank of the Council of Europe]."
|3.||Sickle Cell Anemia (Hemoglobin S Disease)
01/01/2013 - "Molecular matching is superior to serological matching in sickle cell disease patients, decreasing the risk of transfusion reactions, especially delayed transfusion reactions to existing alloantibodies and preventing alloimmunization."
10/01/2012 - "The Mantel-Haenszel risk ratio estimate of combined adult studies showed that women with sickle cell disease had an increased relative risk (27%) on RBC alloantibodies compared with men. "
11/01/2014 - "A selective susceptibility of certain individuals to form multiple alloantibodies in response to red cell transfusion is well-recognized in clinical practice, and is a particular problem in persons with sickle cell disease (SCD). "
08/01/2004 - "We investigated red cell (RBC) alloantibodies in 125 sickle cell anemia (SCA) patients using tube indirect antiglobulin test (PEG, LISS or enzyme) and gel centrifugation test (LISS or enzyme). "
10/01/1996 - "Patients with sickle cell disease are at particular risk for delayed hemolytic transfusion reactions because they may be transfused at intervals over many years; they frequently form alloantibodies because of antigenic differences from the donor population; and they may receive emergency care in different hospitals where transfusion records are not available. "
07/01/2014 - "Alloantibodies are commonly associated with red cell hemolysis. "
01/01/2011 - "Red blood cell alloantibodies can cause severe delayed hemolysis, despite immunosuppression which they receive posttransplantation. "
03/01/2008 - "We describe severe hemolysis due to passenger lymphocyte syndrome (PLS) in all three recipients of organs from a single donor with multiple red cell (RC) alloantibodies. "
03/01/2008 - "A 'dangerous' group O donor: severe hemolysis in all recipients of organs from a donor with multiple red cell alloantibodies."
09/01/2003 - "Hemolysis in these patients probably relates to alloantibodies derived from passenger B lymphocytes transplanted with the organs. "
|5.||Thrombasthenia (Glanzmann Thrombasthenia)
01/01/2011 - "Molecular analysis of a patient with type I Glanzmann thrombasthenia and clinical impact of the presence of anti-αIIbβ3 alloantibodies."
08/01/2006 - "Patients with Glanzmann thrombasthenia (GT) may form isoantibodies which induce refractoriness or inhibition of function of transfused platelets. "
06/01/2002 - "Correlation of activated clotting time (ACT) with rFVLLa infusion and clinical efficacy in a patient with Glanzmann thrombasthenia and platelet alloantibodies."
08/01/1979 - "The management of dental extractions in cases of thrombasthenia complicated by the development of isoantibodies to donor platelets."
12/01/2002 - "Our experience suggests that IA-PA, which restores the haemostatic efficacy of platelet transfusion, is a valuable therapeutic strategy in patients with Glanzmann's thrombasthenia and anti-GPIIb-IIIa isoantibodies."
|3.||Complement System Proteins (Complement)
|4.||von Willebrand Factor
|5.||recombinant FVIIa (rFVIIa)
|6.||Factor VIIa (Activated Factor VII)
|10.||Factor VIII (Coagulation Factor VIII)
|1.||Platelet Transfusion (Blood Platelet Transfusions)
|3.||Blood Transfusion (Blood Transfusions)
|4.||Hematopoietic Stem Cell Transplantation
|5.||Intrauterine Blood Transfusion